Colgate-Palmolive
CL
87.21
-0.04
-0.05%
Colgate-Palmolive
US · CL
#335 by market cap
Listed 1970
87.21
-0.04
-0.05%
Live - 5344 symbols - heartbeat 63s ago
· 2026-10-08 04:00
Pre-market
87.21
0.00%
After-hours
87.21
0.00%
- Market cap
- 69.52B
- P/E (TTM)i
- 34.33
- P/Bi
- 294.63
- EPSi
- 2.63
- Div yieldi
- 2.40%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on CL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.91, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +1.40% YoY
Margins
- Gross margin
- 60.11%
- Operating margin
- 20.77%
- Net margin
- 10.46%
Key ratios & quality
- Enterprise valuei
- 76.34B
- PEG ratioi
- 5.63
- Altman Z-Scorei
- 6.91
PEG uses trailing P/E against the 3-year net income growth rate (6.10%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.54B | 15.69B | 16.47B | 17.42B | 17.97B | 19.46B | 20.10B | 20.38B |
| Gross profit | 9.23B | 9.33B | 10.02B | 10.38B | 10.25B | 11.33B | 12.16B | 12.25B |
| Selling & admin expenses | 5.39B | 5.58B | 6.02B | 6.41B | 6.57B | 7.15B | 7.73B | 7.90B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 3.69B | 3.62B | 3.88B | 3.91B | 3.62B | 4.09B | 4.33B | 4.23B |
| Pretax profit | 3.46B | 3.30B | 3.65B | 3.09B | 2.66B | 3.39B | 3.96B | 3.06B |
| Tax | 906.00M | 774.00M | 787.00M | 749.00M | 693.00M | 937.00M | 907.00M | 798.00M |
| Net profit | 2.56B | 2.53B | 2.86B | 2.34B | 1.97B | 2.46B | 3.05B | 2.26B |
| Basic EPS | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 3 |
| Diluted EPS | 2.75 | 2.75 | 3.14 | 2.55 | 2.13 | 2.77 | 3.51 | 2.63 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.91B | 5.11B | 5.13B | 5.23B | 5.32B | 5.36B |
| Gross profit | 2.99B | 3.07B | 3.05B | 3.15B | 3.23B | 3.30B |
| Selling & admin expenses | 1.90B | 1.96B | 1.97B | 2.07B | 2.08B | 2.13B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.08B | 1.08B | 1.06B | 1.02B | 964.00M | 1.02B |
| Pretax profit | 953.00M | 1.01B | 992.00M | 108.00M | 892.00M | 950.00M |
| Tax | 227.00M | 234.00M | 226.00M | 113.00M | 211.00M | 231.00M |
| Net profit | 726.00M | 773.00M | 766.00M | -5.00M | 681.00M | 719.00M |
| Basic EPS | 1 | 1 | 1 | 0 | 1 | 1 |
| Diluted EPS | 0.85 | 0.91 | 0.91 | -0.05 | 0.80 | 0.86 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 3.79B | 4.18B | 4.34B | 4.40B | 5.11B | 5.28B | 5.32B | 5.71B |
| Cash & ST investments | 726.00M | 883.00M | 888.00M | 832.00M | 775.00M | 966.00M | 1.10B | 1.29B |
| Inventory | 1.25B | 1.40B | 1.67B | 1.69B | 2.07B | 1.93B | 1.99B | 2.03B |
| Total assets | 12.16B | 15.03B | 15.92B | 15.04B | 15.73B | 16.39B | 16.05B | 16.33B |
| Total current liabilities | 3.34B | 4.04B | 4.40B | 4.05B | 4.00B | 4.74B | 5.76B | 6.85B |
| Short-term debt | 12.00M | 659.00M | 404.00M | 188.00M | 133.00M | 425.00M | 767.00M | 1.24B |
| Long-term debt | 6.35B | 7.33B | 7.33B | 7.19B | 8.74B | 8.22B | 7.29B | 6.87B |
| Total liabilities | 11,964,000,000.00 | 14,476,000,000.00 | 14,819,000,000.00 | 14,069,000,000.00 | 14,925,000,000.00 | 15,436,000,000.00 | 15,502,000,000.00 | 15,965,000,000.00 |
| Total equity | 197.00M | 558.00M | 1.10B | 971.00M | 806.00M | 957.00M | 544.00M | 365.00M |
| Retained earnings | 21.62B | 22.50B | 23.70B | 24.35B | 24.57B | 25.29B | 26.15B | 26.60B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.81B | 6.00B | 6.04B | 5.71B | 6.08B | 6.31B |
| Cash & ST investments | 1.11B | 1.22B | 1.28B | 1.29B | 1.34B | 1.37B |
| Inventory | 2.13B | 2.12B | 2.11B | 2.03B | 2.09B | 2.18B |
| Total assets | 16.65B | 17.47B | 17.51B | 16.33B | 16.61B | 16.79B |
| Total current liabilities | 6.86B | 6.78B | 6.50B | 6.85B | 5.93B | 6.15B |
| Short-term debt | 1.70B | 1.61B | 1.11B | 1.24B | 36.00M | 34.00M |
| Long-term debt | 6.57B | 7.14B | 7.31B | 6.87B | 7.94B | 7.82B |
| Total liabilities | 15,914,000,000.00 | 16,418,000,000.00 | 16,275,000,000.00 | 15,965,000,000.00 | 16,124,000,000.00 | 16,224,000,000.00 |
| Total equity | 733.00M | 1.05B | 1.24B | 365.00M | 486.00M | 566.00M |
| Retained earnings | 26.41B | 26.74B | 27.05B | 26.60B | 26.82B | 27.09B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.06B | 3.13B | 3.72B | 3.33B | 2.56B | 3.75B | 4.11B | 4.20B |
| Depreciation & amortization | 511.00M | 519.00M | 539.00M | 556.00M | 545.00M | 567.00M | 605.00M | 630.00M |
| Free cash flow | 2.62B | 2.80B | 3.31B | 2.76B | 1.86B | 3.04B | 3.55B | 3.63B |
| Dividends paid | -1.59B | -1.61B | -1.65B | -1.68B | -1.69B | -1.75B | -1.79B | -1.82B |
| Stock buybacks / issuance | -1.24B | -1.20B | -1.48B | -1.32B | -1.31B | -1.13B | -1.74B | -1.21B |
| Ending cash balance | 726.00M | 883.00M | 888.00M | 832.00M | 775.00M | 966.00M | 1.10B | 1.29B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 600.00M | 884.00M | 1.26B | 1.45B | 747.00M | 995.00M |
| Depreciation & amortization | 148.00M | 151.00M | 158.00M | 173.00M | 156.00M | 155.00M |
| Free cash flow | 476.00M | 776.00M | 1.11B | 1.28B | 609.00M | 867.00M |
| Dividends paid | -406.00M | -474.00M | -420.00M | -523.00M | -417.00M | -462.00M |
| Stock buybacks / issuance | -284.00M | -232.00M | -288.00M | -406.00M | -306.00M | -291.00M |
| Ending cash balance | 1.11B | 1.22B | 1.28B | 1.29B | 1.34B | 1.37B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | 31,560.00 | 626.74 | 320.41 | 353.47 | 455.45 | 703.78 | 1,603.01 |
| ROA %i | 19.33 | 17.41 | 17.41 | 13.99 | 11.60 | 14.32 | 17.81 | 13.17 |
| ROIC %i | -- | 33.34 | 32.16 | 26.42 | 20.96 | 25.52 | 33.29 | 26.24 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | 6,663.21 | 491.97 | 687.22 |
| EBIT margin %i | 23.53 | 22.26 | 23.25 | 18.82 | 15.73 | 18.91 | 21.13 | 16.32 |
| FCF / sales %i | 16.86 | 17.83 | 20.09 | 15.83 | 10.35 | 15.62 | 17.64 | 17.83 |
| Current ratioi | 1.14 | 1.03 | 0.99 | 1.09 | 1.28 | 1.11 | 0.92 | 0.83 |
| Quick ratioi | 0.64 | 0.58 | 0.49 | 0.53 | 0.57 | 0.54 | 0.45 | 0.43 |
| Debt / assetsi | 52.35 | 56.43 | 51.60 | 52.08 | 58.93 | 55.29 | 53.05 | 52.38 |
| LT debt / equityi | -- | 6,687.18 | 1,051.14 | 1,255.34 | 2,278.80 | 1,418.56 | 3,653.30 | 13,553.70 |
| Interest coveragei | 18.95 | 18.19 | 20.93 | 17.08 | 16.93 | 12.82 | 14.55 | 12.46 |
| Revenue CAGR (3Y) %i | -1.03 | 1.08 | 2.15 | 3.87 | 4.61 | 5.71 | 4.89 | 4.29 |
| Net income CAGR (3Y) %i | 20.14 | -1.02 | 10.01 | -3.36 | -8.98 | -5.15 | 10.08 | 6.10 |
| FCF CAGR (3Y) %i | 5.08 | 3.17 | 9.78 | 1.73 | -12.73 | -2.79 | 8.74 | 25.01 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 976.73 | 704.97 | 450.50 | 1,603.01 | 822.05 | 434.54 |
| ROA %i | 17.44 | 17.13 | 16.96 | 13.17 | 12.56 | 11.90 |
| ROIC %i | 34.92 | 33.63 | 33.73 | 26.24 | 26.58 | 24.74 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 21.19 | 21.08 | 20.96 | 16.32 | 15.68 | 15.19 |
| FCF / sales %i | 17.38 | 16.85 | 17.13 | 17.83 | 18.11 | 18.33 |
| Current ratioi | 0.85 | 0.89 | 0.93 | 0.83 | 1.02 | 1.03 |
| Quick ratioi | 0.41 | 0.44 | 0.48 | 0.43 | 0.54 | 0.54 |
| Debt / assetsi | 49.67 | 50.13 | 48.07 | 52.38 | 48.00 | 46.80 |
| LT debt / equityi | 1,810.19 | 1,017.66 | 853.50 | 13,553.70 | 5,473.79 | 3,314.83 |
| Interest coveragei | 14.83 | 15.17 | 15.66 | 12.46 | 12.40 | 12.58 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Oral, Personal and Home Care is the largest reported line at 77.71% of revenue, across 2 reported segments.
- The next-largest line, Hill’s Pet Nutrition, is a distant second at 22.29% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Oral, Personal and Home Care77.71%
Hill’s Pet Nutrition22.29%
Quote time 2026-10-08 04:00:07 · For reference only, not investment advice and not tailored to your situation.